Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press121310.17650/1726-9776-2005-1-2-32-34DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫIntravesical application of Gemicitabine for superficial bladder cancer resistant to intrvesical immunotherapy with BCG vaccineВнутрипузырное применение гемцитабина у больных поверхностным раком мочевого пузыря, резистентным к внутрипузырной иммунотерапии вакциной БЦЖSereginI. V.СерегинИ. В.
Russian Federation
SamoylenkoV. M.СамойленкоВ. М.
Russian Federation
FigurinK. M.ФигуринК. М.
Russian Federation
ЦКВГ ФСБ России, Москва300620051232342002202020022020https://oncourology.abvpress.ru/oncur/article/view/1213

Transurethral removal of tumor with following intravesical chemotherapy with Gemicitabine were performed to 14 patients with superficial bladder cancer relapses after TUR with adjuvant intravesical BCG – therapy. Adjuvant treatment was initiated 2 – 3 weeks after TUR: 1000 mg of gemicitabine was solved in 100 ml of physiologic solution and instillated into the bladder 2 times a week for 3 week. After 1 week break the second course of chemotherapy was carried out.

Treatment was well tolerated by all patients. The follow-up period ranged from 1,5 to 22 months (mean 10,6±7,0 months). After mean period of 11,3 months 10 patients were disease free. Recurrence developed in 4 patients with multifocal bladder relapses. No disease progression was registered. Adjuvand intravesical chemotherapy with Gemicitabine is effective in patients with recurrences of superficial bladder cancer and is well tolerated.

.

1. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. — М., 2001.Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. — М., 2001.2. Solowey M.S., Sofer M., Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of bladder // J. Urol. — 2002;167:1573—1583.Solowey M.S., Sofer M., Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of bladder // J. Urol. — 2002;167:1573—1583.3. Вaniel J., Graus D., Engelstein D. et al. Intravesical BCG treatment for primary T1G3 of the bladder // Europ. Urol. — 1998. — Vol.33. — Supp. 1.Вaniel J., Graus D., Engelstein D. et al. Intravesical BCG treatment for primary T1G3 of the bladder // Europ. Urol. — 1998. — Vol.33. — Supp. 1.4. Lebret Т., Becette V, Barbagelatta M. et al. Can immunomarking with Ki 67 predict BCG response forT1 G3 bladder tumors. // Europ. Urol. — 1998. — Vol. 33. — Suppl. 1.Lebret Т., Becette V, Barbagelatta M. et al. Can immunomarking with Ki 67 predict BCG response forT1 G3 bladder tumors. // Europ. Urol. — 1998. — Vol. 33. — Suppl. 1.5. Dalbagni G., Russo P., Sheinfeld J. et al. Phase 1 trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory trasitional-cell carcinoma of the bladder // J. Clin. Oncol. — 2002; 20:3193—3198.Dalbagni G., Russo P., Sheinfeld J. et al. Phase 1 trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory trasitional-cell carcinoma of the bladder // J. Clin. Oncol. — 2002; 20:3193—3198.6. Beradinis E.D., Antonini G., Peters G.J. et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase 1 study with pharmacodynamic evaluation // Brit. J. Urol. — 2004. — Vol. 93. — Р. 491—494.Beradinis E.D., Antonini G., Peters G.J. et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase 1 study with pharmacodynamic evaluation // Brit. J. Urol. — 2004. — Vol. 93. — Р. 491—494.7. Schoenberg M.P., Haisfield-Wolf M.E., Zuhowski E.G. et al. Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase 1 and Pharmacokinetic Study // Jornal of Clinical Oncology. — 2003. — Vol. 21,4. — Р. 697—703.Schoenberg M.P., Haisfield-Wolf M.E., Zuhowski E.G. et al. Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase 1 and Pharmacokinetic Study // Jornal of Clinical Oncology. — 2003. — Vol. 21,4. — Р. 697—703.